Related Experiment Video

Updated: Sep 28, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options

Begum Yetis Sayin1, Ali Oto2

  • 1Department of Cardiology, Memorial Ankara Hospital, Ankara, Turkey.

Cardiology and Therapy
|March 30, 2022
PubMed

Insights

Left ventricular hypertrophy (LVH) presents diagnostic challenges due to varied causes and presentations. Early identification of treatable conditions like Fabry disease or cardiac amyloidosis is crucial for preventing heart failure and improving patient outcomes.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Pathophysiology

Background:

  • Left ventricular hypertrophy (LVH) diagnosis is complex due to overlapping clinical and morphological features.
  • LVH progression can lead to heart failure, arrhythmias, and increased mortality.
  • Differentiating physiological (athletic heart) from pathological LVH is vital.

Purpose of the Study:

  • To systematically review treatments for diverse patterns of cardiac hypertrophy.
  • To highlight advances in managing LVH caused by specific conditions like Fabry disease, cardiac amyloidosis, and hypertrophic cardiomyopathy.
  • To guide clinicians in preventing cardiovascular events and mortality associated with LVH.

Main Methods:

  • Systematic review of current literature on LVH etiologies and treatments.
  • Analysis of treatment impacts on outcomes for various hypertrophy patterns.
  • Focus on specific conditions: Fabry disease, cardiac amyloidosis, and hypertrophic cardiomyopathy.

Main Results:

  • Common LVH causes include hypertension, aortic valve stenosis, and infiltrative diseases.
  • Management strategies encompass lifestyle changes, medications, surgery, and devices.
  • Specific treatments for Fabry disease, amyloidosis, and hypertrophic cardiomyopathy offer improved prognoses.

Conclusions:

  • Accurate diagnosis of LVH etiology is essential for effective management.
  • Targeted therapies for specific causes of LVH can prevent disease progression and improve survival.
  • Continued research into novel treatments is necessary for optimizing patient care.

Keywords:
AmyloidosisFabry diseaseHypertrophic cardiomyopathyLeft ventricular hypertrophyTreatment of amyloidosisTreatment of left ventricular hypertrophy

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.1K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

24.7K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
52
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
82
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
76
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
44